It has been reported in chronic myelogenous leukemia that GSK3 inhibition does increase the amount of ABCB1 (MDR‐1) mRNA through activation of the WNT/ β‐catenin pathway [42]. This evidence concerns the gene ABCB1 and chronic myelogenous leukemia, BCR-ABL1 positive.